Beclin 1 has been recently shown to possess a Bcl-2 homology-3 (BH3) domain that mediates its interaction with antiapoptotic multidomain proteins. Unlike other BH3-only proteins, Beclin 1 fails to stimulate apoptosis when it is overexpressed. In this issue of Oncogene, Ciechomska et al. report the intriguing finding that Bcl-2, as it interacts with Beclin 1, does not lose its anti-apoptotic potential. This finding may have far-reaching implications for the comprehension of the cross-talk between apoptosis and autophagy.
Ten years ago, Beth Levine and coworkers reported the discovery of Beclin 1, a coiled-coil B60-kDa protein, in a screen for Bcl-2 interacting proteins (Liang et al., 1999) . The gene coding for Beclin 1 maps to a tumor susceptibility locus that is frequently deleted in breast, ovarian and prostate cancers, and its mono-allelic deletion in mice promotes tumorigenesis. Importantly, Beclin 1 is the mammalian ortholog of yeast Atg6 and is essential for macroautophagy (Liang et al., 1999) . In this issue of Oncogene, Aviva Tolkovsky and co-workers (Ciechomska et al., 2009 ) have explored new fascinating aspects of the interaction of Beclin 1 with Bcl-2.
Macroautophagy (that we refer to as 'autophagy') is a catabolic pathway that allows for degrading and recycling intracellular components. This process starts with the formation of double-membrane structures that surround portions of the cytosol or even entire organelles and finally close to form autophagosomes. The fusion of autophagosomes with lysosomes culminates in the degradation of their luminal content, and the catabolic products can then be re-used to maintain cellular homeostasis. Thus, autophagy acts as a cytoprotective mechanism, and its downregulation can accelerate the death of stressed cells. Conversely, autophagosomes are often found in the cytosol of dying cells, coining the expression 'autophagic cell death' . The relationship between autophagy and cell death, in particular Bcl-2-regulated apoptotic cell death, has been a matter of intense studies during the last 5 years. Beclin 1 regulates autophagy in a multiprotein complex that includes class III phosphatidylinositol-3-kinase activity that participates in autophagosome nucleation. In this complex, Beclin 1 interacts with several proteins through domains that are different from the one involved in Bcl-2 binding. The list of regulatory binding partners of Beclin 1 is growing, underscoring the importance of Beclin 1 as a quintessential autophagy regulator.
Recently, a region including amino acids 112-123 from Beclin 1 has been identified as a Bcl-2 homology-3 (BH3) domain (Maiuri et al., 2007; Oberstein et al., 2007) . This domain in Beclin 1 is the minimal sequence necessary for the interaction with antiapoptotic Bcl-2 family of proteins (in particular Bcl-2 itself, Bcl-X L and Mcl-1). BH domains define the members of the Bcl-2 family of proteins and have been numbered BH1-BH4. The only domain present in all Bcl-2 proteins is the BH3 domain, be they anti-or proapoptotic. BH3 domains are involved in the homo-and hetero-dimerization within and between Bcl-2 protein classes. They constitute the only BH domain of the so-called BH3-only proteins, which have been described as proapoptotic proteins (Adams and Cory, 2007) . Overexpression of Bcl-2 (or that of its close homologs Bcl-X L and Mcl-1) confers cytoprotection against a wide range of inducers of apoptosis. By neutralizing proapoptotic Bcl-2 family members, either multidomain proteins (such as Bax and Bax) or BH3-only proteins, Bcl-2 prevents mitochondrial membrane permeabilization and consequent cell death (Adams and Cory, 2007) . As mentioned above, Beclin 1 has been classified as a BH3-only protein. As the BH3 domain is solely responsible for apoptosis induction in a dozen different BH3-only proteins, it might have been expected that Beclin-1 triggers apoptosis, and this is the question that the Tolkovsky lab tackled in their paper.
Undoubtedly, Beclin 1 is required for autophagy, and Bcl-2 regulates apoptosis, but what is the true biological significance of their interaction? Is Bcl-2's role to modulate the pro-autophagy activity of Beclin 1? Or is Beclin 1's role to modulate the anti-apoptotic function of Bcl-2? Several groups have reported that Bcl-2 can sequester Beclin 1, thereby blocking starvation-induced autophagy. This autophagy inhibitory function of Bcl-2 was more effective when Bcl-2 was expressed at the endoplasmic reticulum (ER) rather than at the mitochondria (Pattingre et al., 2005) . Moreover, the transfection-enforced overexpresssion of BH3-only proteins (like Bad) or addition of the pharmacological BH3 domain mimetic ATB737, competitively disrupted the Beclin 1/Bcl-2 interaction and induced autophagy (Maiuri et al., 2007) . Thus, multidomain antiapoptotic proteins of the Bcl-2 family (like Bcl-2, Bcl-X L and Mcl-1) can neutralize the starvation-dependent pro-autophagy activity of Beclin 1 through direct physical interactions. Now, does Beclin 1 neutralize the anti-apoptotic activity of Bcl-2? Intriguingly, a synthetic peptide corresponding to the BH3 domain of Beclin 1 triggers apoptosis when microinjected into cells. However, the transfection-enforced overexpression of the entire Beclin 1 protein does not induce apoptosis (Maiuri et al., 2007) , perhaps because other regions in Beclin 1 neutralize the pro-apoptotic function of the BH3 domain . Reportedly, overexpression of Beclin 1 can induce massive autophagy followed by (non-apoptotic?) cell death, and this effect is more pronounced when one amino acid in the BH3 domain is mutated and the interaction with Bcl-2 is lost (Pattingre et al., 2005) .
In this issue of Oncogene, the Tolkovsky lab has added new clues to the fascinating cross-talk interaction between Beclin 1 and Bcl-2 (Ciechomska et al., 2009), Figure 1 . Despite the fact that Beclin 1 contains a BH3 domain (and hence technically is a BH3-only protein), it failed to neutralize the antiapoptotic function of Bcl-2. The interaction between Beclin 1 and Bcl-2 persisted even when the subcellular localization of wild-type Bcl-2 was redirected to the mitochondria or the ER by introducing organelle-specific targeting sequences into the C-terminus of Bcl-2. Under these conditions, Beclin 1 and Bcl-2 colocalized at the appropriate organelle, as determined by immunoflourescence and by immunoelectron microscopy. Co-immunoprecipitation confirmed that Bcl-2 can 'drag' Beclin 1 (but not a Beclin 1 mutant lacking the Bcl-2-binding domain between amino acids 80 and 150) to any intracellular location. Nonetheless, Bcl-2-mediated cytoprotection against DNA damage, ER stress and death receptor-mediated apoptosis was unaltered by Beclin 1. Beclin 1 even failed to reverse the anti-apoptotic effects of Bcl-2 in autophagy-deficient Atg5 null MEFs (mouse embryonic fibroblasts), eliminating the likelihood of protective feedback by autophagy. In conclusion, it turns out that interaction between Bcl-2 and Beclin 1 is unidirectional rather than mutual: Bcl-2 subverts the pro-autophagy activity of Beclin 1, whereas Beclin 1 fails to annihilate the anti-apoptotic action of Bcl-2 (Ciechomska et al., 2009) .
How can this be explained in molecular terms? One possible scenario would be to postulate that Beclin 1/Bcl-2 heterodimers conserve the same anti-apoptotic activity as Bcl-2 monomers or homodimers. However, this possibility is at odds with the postulated interaction between the Beclin 1 BH3 domain and the BH3 receptor Beclin 1 and Bcl-2 interaction in apoptosis P Boya and G Kroemer domain within Bcl-2 (Maiuri et al., 2007; Oberstein et al., 2007) , which is believed to be required for the anti-apoptotic action of Bcl-2 (Adams and Cory, 2007) . Therefore, in this case Beclin 1 would have to bind to Bcl-2 in a way that does not occupy the BH3-binding groove, or Bcl-2 would have to exert its anti-apoptotic action within the Beclin 1/Bcl-2 complex in a hitherto unsuspected manner, independent from the BH3-binding groove. It has been shown that the pro-apoptotic BH3-only protein t-Bid causes the insertion of Bcl-X L protein into membranes, thereby causing the 'burial' of hydrophobic helix 6 in the lipid bilayer (Billen et al., 2008) . It would be interesting to know whether Beclin-1 causes a similar membrane insertion of Bcl-2 or whether it rather avoids such a potentially pro-apoptotic effect. A second plausible scenario predicts that a pool of Bcl-2 does not bind to Beclin 1 and remains free for its anti-apoptotic function. Bcl-2 is mainly inserted in the outer mitochondrial membrane as well as in ER membranes, whereas Beclin 1 is mainly expressed in the cytosol and the trans-Golgi network. However, depending on the cell type, Beclin 1, especially when it is overexpressed, can be found enriched in intracellular organelles, such as the mitochondria and the ER (Pattingre et al., 2005) . However, the exact degree of colocalization in subcellular organelles of the endogenous proteins in cells should be a matter of investigation for future studies. Importantly, the BH3 domain of Beclin 1 lacks a hydrophobic amino acid at position 119, which reduces its affinity for Bcl-2 as compared with other BH3-only proteins (Feng et al., 2007) . This implies that Bcl-2 would preferentially bind to BH3 proteins other than Beclin 1, unless Beclin 1 was expressed in large molar excess. In other words, Beclin 1 would only bind to free, unoccupied Bcl-2, yet would fail to displace pro-apoptotic BH3-only proteins from their inhibitory interaction with Bcl-2. Intriguingly, threonine 119 of Beclin-1 is phosphorylated by the autophagy inducing DAP kinase and this phosphorylation further reduces the binding of Beclin 1 to Bcl-X L , thereby dissociating the inhibitory Beclin 1/Bcl-X L complex and causing autophagy (Zalckvar et al., 2009) . Recently, phosphorylation of Bcl-2 by c-Jun N-terminal kinase 1 (activated by several apoptotic inducers) has been shown to reduce the interaction of Beclin 1 and Bcl-2 and to induce autophagy. Interestingly, this c-Jun N-terminal kinase 1-dependent phosphorylation preferentially affects the Bcl-2 pool present at the ER (Wei et al., 2008) , in agreement with the earlier data, indicating that only ER-tagged Bcl-2 is able to block starvation induced autophagy (Pattingre et al., 2005) . Thus, posttranslational modifications affecting Beclin 1 or Bcl-2 may regulate the interaction between both proteins in a specific manner, depending on their subcellular localization.
Future investigation must resolve the question why Beclin 1 fails to neutralize the anti-apoptotic action of Bcl-2. Irrespective of this incognita, the most important implication of the work by the Tolkovsky lab (Ciechomska et al., 2009 ) affects the mode of action of Beclin 1 as a tumor suppressor. The failure of Beclin 1 to inhibit the anti-apoptotic function of Bcl-2 indicates that the oncosuppressive action of Beclin 1 cannot be ascribed to its putative pro-apoptotic function and is more likely related to its implication in autophagy. Thus, Beclin 1 exemplifies an atypical BH3-domain-containing protein that fails to induce apoptosis when overexpressed in cells, inaugurating the search for novel types of BH3-only proteins that regulate apoptosis-unrelated processes.
